GlassScriptPhysician profile
Rad Gharavi
NPI 1518078732
$5,970.81
in general payments reported to CMS, 2019-2025
20 companies · $2,243 in 2025
The $2,243 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.73 · 2020: $49.99 · 2021: $830 · 2022: $1,045 · 2023: $633 · 2024: $1,145 · 2025: $2,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,021.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,270.76 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,134.61 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $595.91 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $503.01 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $500.58 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $478.60 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $288.73 | 2022-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $277.80 | 2025 | Auvelity |
| Alkermes, INC. | $248.58 | 2024-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $173.93 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $132.01 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $98.29 | 2022-2024 | Azstarys |
| Harmony Biosciences LLC | $70.04 | 2021 | |
| Jazz Pharmaceuticals INC. | $45.83 | 2021-2022 | |
| Tempus Ai, INC | $44.43 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.03 | 2020 | |
| Idorsia Pharmaceuticals US INC | $21.92 | 2025 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $20.42 | 2023 | Austedo Xr |
| Lundbeck LLC | $15.87 | 2025 | Rexulti |
| Neos Therapeutics, LP | $14.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rad Gharavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.